In a randomised trial of 15 kidney transplant recipients with subclinical graft inflammation, polyclonal Treg infusion did not change graft inflammation at 6 months significantly vs control; inflammation fell in both groups. No adverse events were seen with Tregs.
RCTn = 15
Chandran et al. Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation